Immuno-Biological Laboratories Balance Sheet Health
Financial Health criteria checks 6/6
Immuno-Biological Laboratories has a total shareholder equity of ¥1.1B and total debt of ¥236.0M, which brings its debt-to-equity ratio to 21.5%. Its total assets and total liabilities are ¥1.4B and ¥335.0M respectively.
Key information
21.5%
Debt to equity ratio
JP¥236.00m
Debt
Interest coverage ratio | n/a |
Cash | JP¥629.00m |
Equity | JP¥1.10b |
Total liabilities | JP¥335.00m |
Total assets | JP¥1.43b |
Financial Position Analysis
Short Term Liabilities: 4570's short term assets (¥1.2B) exceed its short term liabilities (¥235.0M).
Long Term Liabilities: 4570's short term assets (¥1.2B) exceed its long term liabilities (¥100.0M).
Debt to Equity History and Analysis
Debt Level: 4570 has more cash than its total debt.
Reducing Debt: 4570's debt to equity ratio has reduced from 47.3% to 21.5% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable 4570 has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: 4570 is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 17.2% per year.